Showing 37 to 48 of 92 results


CRISPR Therapy Shows Promise but Faces Rollout Challenges
The first CRISPR-based therapy, approved in late 2023, offers a cure for previously untreatable diseases; however, slow rollout due to manufacturing and accreditation challenges highlights the need for regulatory adaptations and technological advancements in CRISPR enzyme delivery.
CRISPR Therapy Shows Promise but Faces Rollout Challenges
The first CRISPR-based therapy, approved in late 2023, offers a cure for previously untreatable diseases; however, slow rollout due to manufacturing and accreditation challenges highlights the need for regulatory adaptations and technological advancements in CRISPR enzyme delivery.
Progress
36% Bias Score


World's First Hydrogen Fuel Cell Helicopter Flight Achieved
United Therapeutics successfully completed the world's first hydrogen fuel cell-powered helicopter flight on March 27, 2025, in Bromont, Quebec, advancing their sustainable organ delivery system and showcasing zero-emission aviation technology.
World's First Hydrogen Fuel Cell Helicopter Flight Achieved
United Therapeutics successfully completed the world's first hydrogen fuel cell-powered helicopter flight on March 27, 2025, in Bromont, Quebec, advancing their sustainable organ delivery system and showcasing zero-emission aviation technology.
Progress
48% Bias Score


Taiwanese Entrepreneurs Find Success in Mainland China
Three Taiwanese entrepreneurs—Professor Po-Lin Hsu in medical technology, Christopher Chen in agriculture, and Chiu Pin-ping in rural revitalization—are thriving in mainland China due to supportive policies, showcasing economic and social integration across the strait.
Taiwanese Entrepreneurs Find Success in Mainland China
Three Taiwanese entrepreneurs—Professor Po-Lin Hsu in medical technology, Christopher Chen in agriculture, and Chiu Pin-ping in rural revitalization—are thriving in mainland China due to supportive policies, showcasing economic and social integration across the strait.
Progress
56% Bias Score


Moderna Stock Drops 36% Amidst Falling COVID-19 Vaccine Demand
Moderna (MRNA) stock has fallen 36% this year due to decreased demand for its COVID-19 vaccine, resulting in a 52.6% revenue drop in the last twelve months; however, the company's strong balance sheet and promising vaccine pipeline offer potential for a future turnaround.
Moderna Stock Drops 36% Amidst Falling COVID-19 Vaccine Demand
Moderna (MRNA) stock has fallen 36% this year due to decreased demand for its COVID-19 vaccine, resulting in a 52.6% revenue drop in the last twelve months; however, the company's strong balance sheet and promising vaccine pipeline offer potential for a future turnaround.
Progress
36% Bias Score


Genetically Modified Dire Wolf Pups Created, Raising 'De-Extinction' Debate
Colossal Biosciences announced the creation of three dire wolf pups using genetic engineering, combining ancient DNA with grey wolf surrogates, raising questions about the definition of 'de-extinction' and the success of the project.
Genetically Modified Dire Wolf Pups Created, Raising 'De-Extinction' Debate
Colossal Biosciences announced the creation of three dire wolf pups using genetic engineering, combining ancient DNA with grey wolf surrogates, raising questions about the definition of 'de-extinction' and the success of the project.
Progress
48% Bias Score


Large Language Models Fall Short in Analogical Reasoning
A new study reveals that large language models significantly underperform humans in analogical reasoning, highlighting a critical limitation in their ability to generalize from diverse data and affecting their applicability in various fields, unlike human adaptability to unfamiliar contexts.
Large Language Models Fall Short in Analogical Reasoning
A new study reveals that large language models significantly underperform humans in analogical reasoning, highlighting a critical limitation in their ability to generalize from diverse data and affecting their applicability in various fields, unlike human adaptability to unfamiliar contexts.
Progress
36% Bias Score

CRISPR-Cas9: Revolutionary Gene Editing and Ethical Concerns
CRISPR-Cas9, a gene-editing technology discovered through bacterial immunity research, allows precise DNA modifications with diverse applications, but raises ethical concerns regarding germline editing, as demonstrated by the controversial birth of gene-edited babies in China.

CRISPR-Cas9: Revolutionary Gene Editing and Ethical Concerns
CRISPR-Cas9, a gene-editing technology discovered through bacterial immunity research, allows precise DNA modifications with diverse applications, but raises ethical concerns regarding germline editing, as demonstrated by the controversial birth of gene-edited babies in China.
Progress
16% Bias Score

Novel Antivenom Developed from Hyper-Immune Man's Blood Shows Promise
Scientists created a highly effective antivenom using antibodies from a man who'd been bitten hundreds of times by venomous snakes; mouse trials showed effectiveness against multiple species, potentially revolutionizing snakebite treatment globally.

Novel Antivenom Developed from Hyper-Immune Man's Blood Shows Promise
Scientists created a highly effective antivenom using antibodies from a man who'd been bitten hundreds of times by venomous snakes; mouse trials showed effectiveness against multiple species, potentially revolutionizing snakebite treatment globally.
Progress
40% Bias Score

UK Grants Chinese Researchers Access to 500,000 GP Records Amidst Security Concerns
The UK government approved access for Chinese researchers to 500,000 anonymized UK GP records held by UK Biobank, despite MI5 warnings about potential misuse by Chinese intelligence agencies and a Guardian analysis showing 20% of access applications come from China.

UK Grants Chinese Researchers Access to 500,000 GP Records Amidst Security Concerns
The UK government approved access for Chinese researchers to 500,000 anonymized UK GP records held by UK Biobank, despite MI5 warnings about potential misuse by Chinese intelligence agencies and a Guardian analysis showing 20% of access applications come from China.
Progress
52% Bias Score

Colossal Biosciences Revives Extinct Dire Wolves, Sparking Ethical Debate
Colossal Biosciences announced it successfully recreated three dire wolves from gray wolf cells and surrogate dogs, sparking debate about the ethics and implications of de-extinction efforts versus endangered species conservation.

Colossal Biosciences Revives Extinct Dire Wolves, Sparking Ethical Debate
Colossal Biosciences announced it successfully recreated three dire wolves from gray wolf cells and surrogate dogs, sparking debate about the ethics and implications of de-extinction efforts versus endangered species conservation.
Progress
48% Bias Score

Genetically Modified 'Dire Wolves' Spark De-Extinction Debate
Colossal Biosciences has announced the birth of three dire wolf-gray wolf hybrids, created using ancient dire wolf DNA and gene editing techniques, raising ethical and ecological concerns about de-extinction technology.

Genetically Modified 'Dire Wolves' Spark De-Extinction Debate
Colossal Biosciences has announced the birth of three dire wolf-gray wolf hybrids, created using ancient dire wolf DNA and gene editing techniques, raising ethical and ecological concerns about de-extinction technology.
Progress
40% Bias Score

Health Tech Dominates 2025 Zhongguancun Advanced Technology Competition
The 8th Zhongguancun International Advanced Technology Competition, held in Beijing from March 27-28, 2025, saw eight out of ten finalists focus on health care technologies, reflecting a booming sector projected to reach $1.2 trillion by 2024, and showcasing global collaboration with half of the fin...

Health Tech Dominates 2025 Zhongguancun Advanced Technology Competition
The 8th Zhongguancun International Advanced Technology Competition, held in Beijing from March 27-28, 2025, saw eight out of ten finalists focus on health care technologies, reflecting a booming sector projected to reach $1.2 trillion by 2024, and showcasing global collaboration with half of the fin...
Progress
20% Bias Score
Showing 37 to 48 of 92 results